Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Dentsply Sirona (NASDAQ:XRAY) but lowered the price target from $41 to $38.

May 03, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Dentsply Sirona's Outperform rating is maintained by Barrington Research, though its price target has been reduced from $41 to $38.
While the maintenance of an Outperform rating suggests continued confidence in Dentsply Sirona's business performance and growth potential, the reduction in the price target could reflect adjustments in valuation metrics, market conditions, or company-specific factors. This mixed signal might lead to a neutral short-term impact on the stock price as investors weigh the positive outlook against the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100